coronavirus disease

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

Imiquimod (R 837) is an immune response modifier and a toll-like receptor 7 (TLR7) agonist with antiviral and antitumor effects. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and is commonly employed to induce psoriasis models.

Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.

Amantadine (1-Aminoadamantane) is an antiviral, is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release, and blocks dopamine reuptake.

Anti-inflammatory agent 18 inhibits NO activity (IC50: 15.94 μM) and has an inhibitory effect on the late inflammatory response induced by HMGB1 and can be used to study late inflammatory diseases such as coronavirus disease (COVID-19), sepsis, etc.

Anti-inflammatory agent 19 inhibits NO (IC50: 36.00 μM). anti-inflammatory agent 19 exhibits an inhibitory effect on HMGB1-induced late inflammatory responses. anti-inflammatory agent 19 can be used to study late inflammatory diseases such as Coronavirus disease (COVID-19), sepsis, etc.

Camostat, also known as FOY 305, is a serine protease inhibitor. Camostat is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis. It is an inhibitor of the enzyme transmembrane protease, serine 2 (TMPRSS2). Inhibition of TMPRSS2 partially blocked infection by SARS-CoV and Human coronavirus NL63 in HeLa cell cultures. In vitro study showed that camostat significantly reduces the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.

SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), with potent inhibitory activity (IC50: 3.8 nM) and 9.0% oral bioavailability (BA), used in COVID-19 research [1].

SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, showing potent inhibitory activity with an IC50 of 4.9 μM, and is used in the research of coronavirus disease 2019 (COVID-19).

Olendalizumab is a humanized monoclonal antibody targeting complement component C5a. Olendalizumab blocks the interaction between C5a and receptor C5aR(CD88) by specifically binding C5a, thus inhibiting C5a-mediated inflammatory reaction and chemotaxis and activation of neutrophils. Olendalizumab is used for inflammatory diseases mediated by complement, such as sepsis, graft-versus-host disease (GVHD) and viral infection (such as COVID-19).

Plonmarlimab (TJ003234) is a humanized monoclonal antibody and a specific neutralizing antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF/CSF2). Plonmarlimab binds to and neutralizes GM-CSF with high affinity, blocking its binding to receptor complexes. This inhibits the activation of the downstream JAK2-STAT5 pathway, reduces the recruitment of various inflammatory cells and the release of pro-inflammatory factors, thereby alleviating tissue inflammation and damage. In a mouse model of macrophage activation syndrome (MAS), Plonmarlimab significantly improved disease progression, including weight loss and anemia. Plonmarlimab can be used in research on immune diseases and antiviral studies.